Joal D Beane

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4387824/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Neoadjuvant Therapy for Pancreatic Cancer: Increased Use and Improved Optimal Outcomes. Journal of the American College of Surgeons, 2022, 234, 436-443.	0.5	11
2	Real-time mortality risk calculator following pancreatoduodenectomy: quantifying the impact of perioperative events. Hpb, 2022, , .	0.3	0
3	Optimal Pancreatic Surgery. Annals of Surgery, 2021, 274, e355-e363.	4.2	48
4	Small pancreatic neuroendocrine tumors: Resect or enucleate?. American Journal of Surgery, 2021, 222, 29-34.	1.8	16
5	500 Minimally Invasive Robotic Pancreatoduodenectomies. Annals of Surgery, 2021, 273, 966-972.	4.2	112
6	Surgeon experience contributes to improved outcomes in pancreatoduodenectomies at high risk for fistula development. Surgery, 2021, 169, 708-720.	1.9	22
7	Regulatory T-cell and neutrophil extracellular trap interaction contributes to carcinogenesis in non-alcoholic steatohepatitis. Journal of Hepatology, 2021, 75, 1271-1283.	3.7	162
8	Impact of cancer center accreditation on outcomes of patients undergoing resection for hepatocellular carcinoma: A SEER-Medicare analysis. American Journal of Surgery, 2021, 222, 570-576.	1.8	0
9	The effect of high intraoperative blood loss on pancreatic fistula development after pancreatoduodenectomy: An international, multi-institutional propensity score matched analysis. Surgery, 2021, 170, 1195-1204.	1.9	11
10	Neutrophils Extracellular Traps Inhibition Improves PD-1 Blockade Immunotherapy in Colorectal Cancer. Cancers, 2021, 13, 5333.	3.7	29
11	Novel Techniques and the Future of HIPEC (Immunotherapy, Viral Therapy). , 2020, , 221-234.		1
12	ASO Author Reflections: Pleuropulmonary Recurrence Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Appendiceal Pseudomyxoma Peritonei. Annals of Surgical Oncology, 2019, 26, 581-582.	1.5	0
13	Robotic pancreatoduodenectomy with vascular resection: Outcomes and learning curve. Surgery, 2019, 166, 8-14.	1.9	52
14	Associations of CDH1 germline variant location and cancer phenotype in families with hereditary diffuse gastric cancer (HDGC). Journal of Medical Genetics, 2019, 56, 370-379.	3.2	33
15	Pleuropulmonary Recurrence Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Appendiceal Pseudomyxoma Peritonei. Annals of Surgical Oncology, 2019, 26, 1429-1436.	1.5	7
16	Variation in Drain Management After Pancreatoduodenectomy. Annals of Surgery, 2019, 269, 718-724.	4.2	54
17	Risk Factors and Mitigation Strategies for Pancreatic Fistula After Distal Pancreatectomy. Annals of Surgery, 2019, 269, 143-149.	4.2	142
18	Identification of an Optimal Cut-off for Drain Fluid Amylase on Postoperative Day 1 for Predicting Clinically Relevant Fistula After Distal Pancreatectomy. Annals of Surgery, 2019, 269, 337-343.	4.2	42

JOAL D BEANE

#	Article	IF	CITATIONS
19	The Beneficial Effects of Minimizing Blood Loss in Pancreatoduodenectomy. Annals of Surgery, 2019, 270, 147-157.	4.2	43
20	Assessing the impact of conversion on outcomes of minimally invasive distal pancreatectomy and pancreatoduodenectomy. Hpb, 2018, 20, 356-363.	0.3	42
21	Characterization and Optimal Management of High-risk Pancreatic Anastomoses During Pancreatoduodenectomy. Annals of Surgery, 2018, 267, 608-616.	4.2	117
22	Pancreatogastrostomy Vs. Pancreatojejunostomy: a Risk-Stratified Analysis of 5316 Pancreatoduodenectomies. Journal of Gastrointestinal Surgery, 2018, 22, 68-76.	1.7	19
23	Incorporation of Procedure-specific Risk Into the ACS-NSQIP Surgical Risk Calculator Improves the Prediction of Morbidity and Mortality After Pancreatoduodenectomy. Annals of Surgery, 2017, 265, 978-986.	4.2	88
24	Pancreatoduodenectomy with venous or arterial resection: a NSQIP propensity score analysis. Hpb, 2017, 19, 254-263.	0.3	35
25	The model for end-stage liver disease predictsÂoutcomes in patients undergoing cholecystectomy. Surgical Endoscopy and Other Interventional Techniques, 2017, 31, 5192-5200.	2.4	16
26	Transcriptomic profiling and quantitative high-throughput (qHTS) drug screening of CDH1 deficient hereditary diffuse gastric cancer (HDGC) cells identify treatment leads for familial gastric cancer. Journal of Translational Medicine, 2017, 15, 92.	4.4	14
27	Vascular challenges from pancreatoduodenectomy in the setting of coeliac artery stenosis. BMJ Case Reports, 2017, 2017, bcr2016217943.	0.5	3
28	Risk-adjusted Outcomes of Clinically Relevant Pancreatic Fistula Following Pancreatoduodenectomy. Annals of Surgery, 2016, 264, 344-352.	4.2	144
29	The Characterization and Prediction of ISCPF Grade C Fistulas Following Pancreatoduodenectomy. Journal of Gastrointestinal Surgery, 2016, 20, 262-276.	1.7	108
30	Distal pancreatectomy with celiac axis resection: what are the added risks?. Hpb, 2015, 17, 777-784.	0.3	46
31	Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma. Clinical Cancer Research, 2015, 21, 2278-2288.	7.0	310
32	Quantifying the Burden of Complications Following Total Pancreatectomy Using the Postoperative Morbidity Index: A Multi-Institutional Perspective. Journal of Gastrointestinal Surgery, 2015, 19, 506-515.	1.7	24
33	Duodenal ischemia and upper GI bleeding are dose-limiting toxicities of 24-h continuous intra-arterial pancreatic perfusion of gemcitabine following vascular isolation of the pancreatic head: early results from the Regional Chemotherapy in Locally Advanced Pancreatic Cancer (RECLAP) study. Investigational New Drugs, 2015, 33, 109-118.	2.6	9
34	Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma. Molecular Therapy, 2015, 23, 1380-1390.	8.2	88
35	Establishing a Quantitative Benchmark for Morbidity in Pancreatoduodenectomy Using ACS-NSQIP, the Accordion Severity Grading System, and the Postoperative Morbidity Index. Annals of Surgery, 2015, 261, 527-536.	4.2	73
36	Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts. Surgery, 2015, 158, 881-889.	1.9	9

JOAL D BEANE

#	Article	IF	CITATIONS
37	Defining the post-operative morbidity index for distal pancreatectomy. Hpb, 2014, 16, 915-923.	0.3	32
38	ls American College of Surgeons NSQIP Organ Space Infection a Surrogate for Pancreatic Fistula?. Journal of the American College of Surgeons, 2014, 219, 1111-1116.	0.5	33
39	Optimal management of delayed gastric emptying after pancreatectomy: An analysis of 1,089 patients. Surgery, 2014, 156, 939-948.	1.9	31
40	Efficacy of Adjuvant Radiation Therapy in the Treatment of Soft Tissue Sarcoma of the Extremity: 20-year Follow-Up of a Randomized Prospective Trial. Annals of Surgical Oncology, 2014, 21, 2484-2489.	1.5	180
41	Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: Results of the GYMSSA trial. Journal of Surgical Oncology, 2014, 110, 275-284.	1.7	159
42	p85β regulatory subunit of class IA PI3 kinase negatively regulates mast cell growth, maturation, and leukemogenesis. Blood, 2012, 119, 3951-3961.	1.4	10
43	Dimethylamino Parthenolide Enhances the Inhibitory Effects of Cemcitabine in Human Pancreatic Cancer Cells. Journal of Gastrointestinal Surgery, 2012, 16, 1333-1340.	1.7	26
44	Outcomes after preoperative endoscopic ultrasonography and biopsy in patients undergoing distal pancreatectomy. Surgery, 2011, 150, 844-853.	1.9	53
45	Splenic Preserving Distal Pancreatectomy: Does Vessel Preservation Matter?. Journal of the American College of Surgeons, 2011, 212, 651-657.	0.5	55
46	Robotic distal pancreatectomy: Cost effective?. Surgery, 2010, 148, 814-823.	1.9	225
47	The Role of AKT in Soft Tissue Sarcoma: Review and Insights. Molecular Cancer Research, 0, , .	3.4	Ο